Author:
Arai N.,Isaji M.,Miyata H.,Fukuyama J.,Mizuta E.,Kuno S.
Publisher
Springer Science and Business Media LLC
Subject
Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Neurology (clinical),General Neuroscience
Reference10 articles.
1. Akai T, Ozawa M, Yamaguchi M, Mizuta E, Kuno S (1995) Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys. Jpn J Pharmacol 67: 117–124
2. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546–4550
3. Calne DB (1993) Treatment of Parkinson's disease. N Engl J Med 329: 1021–1027
4. Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR (1987) Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 78: 273–280
5. Clemens JA, Okimura T, Smalstig EB (1993) Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior. Arzneimittelforschung/Drug Res 43: 281–286
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献